Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Social Concept

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Social Concept. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-001560-35 Sponsor Protocol Number: 2358 Start Date*: 2016-04-07
    Sponsor Name:Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands
    Full Title: Bumetanide in Autism Medication and BIomarker study
    Medical condition: Autism Spectrum Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005000-17 Sponsor Protocol Number: CAFQ056A2225 Start Date*: 2013-08-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton...
    Medical condition: obsessive compulsive disorder (OCD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 100000004873 10002862 Anxiety disorders NEC (incl obsessive compulsive disorder) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001288-18 Sponsor Protocol Number: 16-API-01 Start Date*: 2019-01-08
    Sponsor Name:CHU de Nice
    Full Title: ASIC channels and migraine disorders - Proof of concept study on the efficacy of Amiloride in prophylaxis of Migraine with Aura - APAM study
    Medical condition: Migraine with aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011819-20 Sponsor Protocol Number: V00067 CA 201 1A Start Date*: 2009-05-29
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study.
    Medical condition: Adult patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome, with implantable cardioverter defibrillator (ICD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057926 Long QT syndrome congenital LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002569-20 Sponsor Protocol Number: BIELEFELD-Janssen-PHRCN-2017 Start Date*: 2018-11-06
    Sponsor Name:CHU Dijon Bourgogne
    Full Title: A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of ustekinumab in association with prednisone, for the treatment of non-infectious severe uveitis (NISU)
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10046851 Uveitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005088-82 Sponsor Protocol Number: CAFQ056A2204 Start Date*: 2008-05-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of mul...
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003466-33 Sponsor Protocol Number: 1103-011 Start Date*: 2013-05-17
    Sponsor Name:Mental Health Services North Holland North
    Full Title: Memantine Add-On Therapy to Clozapine
    Medical condition: Cognitive functioning, severity of psychopathology and treatment response (positive symptoms and negative symptoms of schizophrenia), depressive symptoms, social cognition, obsessive-compulsive sy...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002332-81 Sponsor Protocol Number: IB2019-03 Start Date*: 2019-11-08
    Sponsor Name:Institut Bergonié
    Full Title: CombinatiOn of NivolumAb plus Relatlimab in patients with Advanced or metastatic soft-tissue Sarcoma: a proof-of-concept randomized phase II study
    Medical condition: Advanced soft-tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001273-23 Sponsor Protocol Number: 2021NanoLi-CT01 Start Date*: 2021-09-20
    Sponsor Name:MEDESIS PHARMA SA
    Full Title: A prospective, multicenter, with a first part randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period trial to evaluate the clinical safety and ef...
    Medical condition: Sufficient clinical and paraclinical information for the diagnosis of Alzheimer’s Disease (AD) according to the international diagnosis criteria from McKhann G. M. et al. 2011
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003249-34 Sponsor Protocol Number: F13640GE209 Start Date*: 2007-09-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinationa...
    Medical condition: Patients who have failed adaptation of opioid therapy for cancer pain
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000620-17 Sponsor Protocol Number: PPL17 Start Date*: 2019-05-08
    Sponsor Name:Dilafor AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening...
    Medical condition: Induction of labor in pregnant women with unripe cervix
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10055563 Labor induction LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002295-13 Sponsor Protocol Number: APHP200552 Start Date*: 2020-10-15
    Sponsor Name:Assistance Publique - Hôpitaux Paris
    Full Title: Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of conc...
    Medical condition: The study population will consist of adults (18-80 years old) hospitalised for ≤48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test posit...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002390-25 Sponsor Protocol Number: E21-04 Start Date*: 2022-01-20
    Sponsor Name:Fab'entech
    Full Title: A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxyge...
    Medical condition: COVID-19 in hospitalized patients in need of supplemental oxygen and at risk of severe outcome
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003653-16 Sponsor Protocol Number: S62092 Start Date*: 2019-03-21
    Sponsor Name:UZ Leuven
    Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study
    Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10072959 Birdshot chorioretinopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001087-11 Sponsor Protocol Number: 15112SMcI-SS Start Date*: 2016-06-23
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Chemoprevention in BRCA1 mutation carriers - a proof of concept study
    Medical condition: BRCA1 mutation carrier Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10041244 - Social circumstances 10064117 Familial risk factor PT
    20.0 10041244 - Social circumstances 10064117 Familial risk factor PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023047-15 Sponsor Protocol Number: CC-4047-SSC-001 Start Date*: 2012-03-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC...
    Medical condition: systemic sclerosis associated with interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024087-17 Sponsor Protocol Number: MAG104615 Start Date*: 2011-11-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) DK (Completed) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002139-94 Sponsor Protocol Number: IPH1101-203 Start Date*: 2007-06-19
    Sponsor Name:Innate Pharma
    Full Title: Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients
    Medical condition: Non previously treated Hepatitis C patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002407-18 Sponsor Protocol Number: FFCD1703 Start Date*: 2020-03-24
    Sponsor Name:Federation Francophone de Cancerologie Digestive
    Full Title: FFCD 1703 -POCHI PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STU...
    Medical condition: MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA